venture capital

Latest Headlines

Latest Headlines

Biotech in China is built brick-by-brick, but more money would help, BeiGene's Oyler says

Chemistry and biology are joining hands in China in ways that will have a profound impact on biotechnology startups and more established companies, but it is still early days for many companies and more money from venture capitalists or other funding sources is welcome.

TrialReach raises $13.5M to connect patients with studies

London startup TrialReach hauled in $13.5 million in Series B cash, funds that will help expand its technology designed to connect patients with their ideal clinical trials.

Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests

U.K. diagnostics outfit Atlas Genetics roped in $20 million in Series C financing to develop its ultrarapid point-of-care tests for infectious diseases, gearing up for a European launch of the product and expanding its foothold in a growing market.

$4B VC shop lays out its vision for the future of digital health

Anyone with a passing interest in tech startups is unlikely to be shocked by Silicon Valley VC Andreessen Horowitz listing digital health as one of its top 16 trends. But as one of the organizations with some power over how these trends play out, the reasoning behind Andreessen Horowitz's list makes for interesting reading.

Novartis teams with Qualcomm on $100M digital health fund

The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.

For Q3, a dismal record of diagnostics venture investment

For the medical diagnostics industry, 2014 is looking like a seesaw in terms of venture investment trends.

In Q2, diagnostics venture investment showed some signs of life

This summer, venture investment trends have given the medical diagnostics industry reason for at least a little optimism.

Top 20 licensing deals show shrinking dollar amounts

Most biotech analysts have been concentrating heavily on the weakened flow of venture dollars into the industry. But if you look at the licensing side of the business, you'll also find some solid reasons for concern.

Merck to invest in Canadian VC fund

It takes money to make money and yet another pharmaceutical maker is partnering in a venture capital fund, this one designed to draw drug companies to Quebec.

Quintiles partners with Russians on new drug development ventures

A venture group backed by the Russian government and tasked with building a drug development industry in the country is partnering with Quintiles to go to work on the clinical trial end of the...